Brain metastasis risk in non-small cell lung cancer
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This study looks at the risk and outlook for non-small cell lung cancer that spreads to the brain. It aims to learn more about who gets brain metastasis and how it affects patients, which could help guide treatment decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer.
- You are 18 years or older.
- You are in generally good health (KPS score 70 or higher).
- You have had full body imaging including a brain MRI before starting treatment.
- You are receiving standard lung cancer treatment.
- You are able and willing to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether some people with brain metastases from solid tumors can safely skip radiation if their cancer drugs (like targeted therapy, immunotherapy, or certain chemotherapies) shrink the brain tumors. You will get MRI scans to see if the drugs are working.
This trial looks at people with non-small cell lung cancer that has spread to the brain or the membranes around the brain. It aims to learn more about patients who are already scheduled for brain surgery, such as removing a tumor or placing a drain.
This study looks at how people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord are treated in real-world clinics in China. If you have received treatment for this spread since 2018, you may be able to help doctors learn what works best.
This study uses an artificial intelligence (AI) tool to look at your scans and health information to better predict whether lung cancer might spread to the brain and how the disease may progress. It aims to help doctors make more personalized treatment decisions.
This trial looks at whether the timing of radiation therapy and immunotherapy (like Keytruda or Opdivo) affects outcomes in patients with non-small cell lung cancer (NSCLC) that has spread to the brain. You would receive both treatments as part of your normal care, and the study will track how you do.
This study tests whether giving radiation therapy (called stereotactic radiotherapy) to the brain before or along with a combination of an experimental drug (ivonescimab) and chemotherapy can help treat non-small cell lung cancer that has spread to the brain. It compares this approach to just receiving the drug and chemotherapy without the brain radiation.
Hear when a new Brain Metastases From Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.